Rami joined Arcellx in 2021 and serves as our Chairman and Chief Executive Officer. Most recently, Rami served as President and CEO of Nevro, beginning in 2012. Under his leadership, Nevro grew from a small private company to a public company approaching $400m in revenue and a leader in neuromodulation. Prior to Nevro, Rami was an investor with Johnson & Johnson Development Corporation (JJDC), where he led several investments including Nevro’s Series B Financing and served on the Board of Directors of several private companies including Nevro’s. Prior to joining JJDC, Rami was a Design Engineer for Advanced Neuromodulation Systems, Inc. where he led firmware design and development on several implantable spinal cord stimulators. Rami earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the US and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues. Rami received an MBA from the Wharton School of Business at the University of Pennsylvania and holds a BS in Electrical and Computer Engineering from Rutgers University School of Engineering.

Chris has served as Arcellx’s Chief Medical Officer since April 2021. Prior to that, he served as Chief Medical Officer of Precision BioSciences and Bavarian Nordic. At Precision, he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. While at Bavarian Nordic, he oversaw clinical development programs for its immune-oncology and infectious disease vaccine portfolio. Prior to his roles in biotech, he was head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI). He joined NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and held an Adjunct Appointment in the Genitourinary Malignancies Branch. At NCI, Dr. Heery was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer. Dr. Heery is board-certified in Medical Oncology and Internal Medicine and completed his internal medicine residency at the University of Illinois at Chicago after receiving his MD from East Carolina University Brody School of Medicine. Dr. Heery also holds a BA in English Literature from Duke University.

Kate, an accomplished human resources business leader, brings more than 20 years of cross-industry experience, building and managing high-caliber HR organizations and partnering with business leaders to support the growth of industry-leading companies. Kate joins Arcellx from McKesson Corporation where she held roles with increasing responsibility since 2013, most recently serving as Senior Vice President, Human Resources, as part of the company’s Prescription Technology Solutions business unit. In this role Kate was part of an HR transformation that integrated a disruptive start-up into McKesson, which served as a springboard for her interest in rejoining a smaller, entrepreneurial company. Prior to McKesson, Kate spent 10 years at Gap, Inc. in several leading roles, most recently as Vice President, Human Resources. From 1999-2003, Kate was Vice President and Head of Human Resources at Oxygen Media, a start-up in the media and entertainment space. Kate holds an MBA in Business Strategy from New York University and a BA in Government from Dartmouth College.

Mike brings nearly 25 years of experience in pharma and biotech strategy and licensing. Most recently, Mike served as SVP of Corporate Development for Precision BioSciences, where he led transactions worth more than $2 billion, including a CAR-T co-development and co-promotion partnership with Baxalta that won the 2016 LES Deal of Distinction award, and in vivo gene editing collaborations with Gilead and The University of Pennsylvania’s Gene Therapy Program. Previously, Mike worked at GlaxoSmithKline in R&D Strategy and Portfolio Management, supporting portfolio analysis, business development, innovations in clinical trial design, evaluation and adoption of digital transformation initiatives, and optimization of global IP filings. Mike has worked with a wide range of start-up, small, medium, and large therapeutics companies, both private and public, and was a co-founder of Cempra Pharmaceuticals. Mike holds an MBA from Duke University’s Fuqua School of Business, an MPP. from Duke University’s Sanford School of Public Policy, and a BS in Biology from the Duke University Trinity College of Arts and Science.

Aileen joined Arcellx in 2021 and currently serves as our Chief Business Officer. Prior to joining Arcellx, Aileen held many roles with increasing responsibility at Nevro Corporation including Chief of Staff to the Chief Executive Officer, Associate Director, Business Development and Strategy, and as a Director of Marketing where she was instrumental in leading the go-to-market commercial strategy for a new clinical indication. Prior to Nevro, Aileen was a management consultant at Deloitte Consulting, partnering with a wide range of companies across the healthcare sector, and held business development and marketing roles at multiple digital health startups. Aileen started her career at Morgan Stanley where she was a Finance Analyst. Aileen received an MBA from the Wharton School of the University of Pennsylvania and holds a BA in Economics from the Wharton School of the University of Pennsylvania.

Michelle Gilson joined Arcellx, Inc. as our chief financial officer in May 2022. Most recently, Ms. Gilson served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, covering biotechnology companies. Prior to joining Canaccord, Ms. Gilson held biotechnology equity research roles at Jefferies, LLC; Instinet, LLC (Nomura Securities); Oppenheimer & Co. Inc.; and Goldman Sachs. Ms. Gilson earned her B.S. in Business Administration from the University of Southern California.

Narinder joined Arcellx in Oct 2021 and serves as our Chief Technical Officer. Narinder has over two decades of technical and operational leadership experience in end-to-end biopharmaceutical clinical development, commercialization, and life cycle management. Previously, Narinder was CTO for Forte Biosciences, and prior to Forte, he served as EVP Technical Operations at Aimmune Inc. Prior to Aimmune, Narinder led neoantigen-based personalized cancer vaccine and T cell therapy development as SVP, Pharmaceutical Sciences and Manufacturing at Genocea. Prior to Genocea, Narinder served in a variety of technical leadership roles in drug product and combination device development, commercialization, and manufacturing operations at Momenta Pharmaceuticals and at Amgen. Narinder holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from the Indian Institute of Technology, Delhi, an MS in Chemical Engineering from the University of Houston, and an MBA from the UCLA Anderson School of Management.

Neeraj joined Arcellx in April 2021 and serves as our Chief Commercial Officer. Prior to joining Arcellx, Neeraj served as the Vice President of Marketing at Nevro. Over his 7 years at Nevro, he and his team set and executed commercial plans for a business that grew to ~$400 MM. His responsibilities included product and clinical portfolio strategy, branding, demand generation, key thought leader engagement, professional education, sales analytics and sales training. Prior to Nevro, Neeraj worked in the medical device sector at Johnson & Johnson for 17 years where he had various roles within Marketing, Licensing & Acquisitions and Research & Development. Neeraj received an MBA from the Kellogg School of Management at Northwestern University and has a BS in Electrical Engineering from the University of Illinois at Urbana-Champaign.

David has served as Chief Scientific Officer since July 2021 and has over 20 years of biopharmaceutical research and drug development experience in oncology. Prior to joining Arcellx in 2020 as Vice President, Research and Translational Sciences, David spent 18 years at MedImmune, the global biologics research and development unit of AstraZeneca, where he held roles of increasing responsibility. While serving as the head of the antibody drug conjugate strategic area at AstraZeneca, David managed a portfolio of over 20 pipeline projects spanning discovery to Phase I. Prior to this experience, David worked at Genentech where he focused on genomics-based target discovery and monoclonal antibody targeting in cancer. David received his BS in Biology from Virginia Tech before receiving his PhD from the University of Virginia.

Maryam joined Arcellx as our General Counsel in June 2022. Most recently, she served as Deputy General Counsel at Kinnate Biopharma Inc. Prior to Kinnate, she was Assistant General Counsel, Corporate at AstraZeneca Pharmaceuticals LP, where she led negotiations for numerous complex strategic transactions, including a landmark license deal with the University of Oxford for global rights to the ChAdOx1 COVID-19 vaccine. Previously, Maryam held the position of Associate, Corporate & Securities at Pepper Hamilton LLP (now Troutman Pepper). She began her career as Study Technician/Assistant Toxicologist, Genetic Toxicology at Covance Labs Inc. (now Labcorp); and Clinical Marketing Specialist, Global Marketing at Given Imaging Ltd. (now Medtronic). Maryam holds a JD from Georgetown University Law Center, an MS in Biotechnology/Regulatory Affairs from Johns Hopkins University, and a BS in Laboratory Animal Science from North Carolina Agricultural and Technical State University. She is an attorney licensed by the Supreme Court of Pennsylvania and registered with the State Bar of California.

Doug joined Arcellx in October, 2022 and serves as our Vice President of Quality. Prior to joining Arcellx Doug served as Vice President of Quality at Nevro. During that time he and the Quality team supported the rapid ramp in commercial production immediately after FDA approval for the Senza product. In addition to managing all aspects of product quality for an outsourced production model the organization was also responsible for supporting new product development, handling technical inquiries from physicians, patients and Nevro representatives and managing customer complaints. The organization also managed external audits and inspections by their notified body and the FDA. Prior to Nevro, Doug spent more than 30 years working in variety of Quality and Operations roles with both small (AngioScore, Aegea Medical) and large (Baxter, Boston Scientifc, Aventis Behring) medical product companies. Doug has a BS Chemical Engineering degree from Cornell University and an MS Chemical Engineering degree from Illinois Institute of Technology. He also has an MBA and MS Industrial Engineering degree from the University of Illinios at Chicago.

Brad joined Arcellx in March 2021, bringing over 30 years of experience in developing, testing, and commercializing medical technologies. Most recently, Brad served as VP of Clinical and Regulatory for Nevro, leading the clinical trials and regulatory approvals to bring a more effective spinal cord stimulation system to patients with chronic pain. Prior to this, Brad was VP of Research at Northstar Neuroscience, investigating numerous neuromodulation applications such as hemiparesis following stroke, major depressive disorder, movement disorders, and tinnitus. He was co-founder and Director of Research at Heartstream, which revolutionized automatic external defibrillators (AEDs), expanding their use from professional medical providers to ubiquitous availability. Brad received an MS degree in Biomedical Engineering from Johns Hopkins University and a BS in Electrical Engineering from the University of Illinois, Urbana-Champaign, IL.

Shashi has over 25 years of experience in biological CMC development and manufacturing from preclinical development through commercialization. Prior to joining Arcellx, Shashi was head of Process Development at Jazz. Previously, Shashi held various CMC leadership positions at Alexion, Synageva, Zyngenia, Teva, Cogenesys, and Human Genome Sciences. Shashi holds a PhD in Biochemistry.

Myesha joined Arcellx in June 2021, bringing over 25 years of experience as a communications professional providing strategy, development, and execution of internal and external communications programs for publicly traded pharmaceutical and biotechnology companies. Most recently, Myesha was Vice President, Investor Relations and Corporate Communications at Adverum Biotechnologies. Prior to this Myesha held the same role at Global Blood Therapeutics, Inc., a $3 billion market capitalization company. Previously, Myesha led the integrated communications function at ZS Pharma, Inc. (acquired by AstraZeneca PLC), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma), and served in various communications roles with increasing responsibility at other publicly traded biotechnology companies. Myesha earned a BA in Business from Holy Names University.

Prior to Arcellx, Brian held multiple roles within Bristol Myers Squibb (formerly Celgene) where he worked over a decade on the development and commercialization of cellular therapies. Most recently, he was Senior Director of Process Engineering in Global Manufacturing Science and Technology, where he was responsible for late-stage lifecycle management, facility design, and technical transfer for multiple CAR-T assets. Brian has led technical transfers to internal sites and CMOs, oversaw the PPQ program for a CAR-T product, and contributed to BLA/MAA submissions. Brian previously led the Process Development department in the development of allogeneic cell therapies, represented Technical Operations on global project teams, and led teams in Analytical Development. Brian oversaw the CMC sections for multiple IND submissions for new therapeutic candidates, and he has a history of working with health authorities on novel products from pre-IND through pre-BLA meetings. Prior to working in cell and gene therapies, Brian worked in vaccine manufacturing at Merck. Brian has a PhD in Chemical and Biomolecular Engineering from the University of Pennsylvania.